Starting stock price: $2.55
Ending stock price: $0.53
Percent Change: -79.22%
Details: Cytogen has four marketed products and is developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. The company's stock declined steadily through the second half of 2007. In November Cytogen told analysts that the company was hiring an investment firm to examine its "strategic alternatives." Those alternatives--designed to satisfy the never-ending pursuit of maximizing shareholder value--ranged from licensing new products to selling the company or merging.
Cytogen execs hit the road. Report
Cytogen to raise $10.1M. Report